MGMT and cancer: For more than half of patients with O6–methylguanine methyltransferase (MGMT) unmethylated cancers, fewer than 15% derive benefit from temozolomide (TMZ).1 Among MGMT methylated patients, as many as half may have progressive disease while receiving the standard of care.2 In the relapsed or progressive disease setting, no routinely effective therapy has emerged.